Anti-CD20 treatment of relapsed or refractory immune thrombocytopaenic purpura (ITP) after first line corticosteroid treatment

ISRCTN ISRCTN16619820
DOI https://doi.org/10.1186/ISRCTN16619820
Secondary identifying numbers HO64
Submission date
20/12/2005
Registration date
20/12/2005
Last edited
14/11/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Haematological Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Dr H.R. Koene
Scientific

Academic Medical Centre (AMC)
Department of Haematology
Postbus 22660
Amsterdam
1100 DE
Netherlands

Phone +31 (0)20 566 9111
Email h.r.koene@amc.uva.nl

Study information

Study designMulticentre, randomised, active controlled, parallel group trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific title
Study acronymHOVON 64 ITP
Study objectivesThe percentage of patients reaching complete response (CR), good response (GR) or moderate response (MR) in each treatment arm is greater than 50%.
Ethics approval(s)Received from the local medical ethics committee
Health condition(s) or problem(s) studiedImmune thrombocytopaenic purpura (ITP)
InterventionAll patients will be randomised between:
Arm A: conventional dose rituximab 375 mg/m^2, 4 weekly doses
Arm B: conventional dose rituximab 375 mg/m^2, 2 weekly + 2 weekly doses, dependent on response
Arm C: high dose rituximab 750 mg/m^2, 2 weekly doses
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Rituximab
Primary outcome measureThe response (CR/GR/MR/NR) to treatment.
Secondary outcome measures1. Need for emergency treatment (platelet count less than 10 or haemorrhagic diathesis, haemorrhage/bleeding defined by grade 3 or 4 according to NCI CTCAE v3.0)
2. Time to treatment failure/relapse
Overall study start date01/09/2005
Completion date01/05/2008

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants150
Key inclusion criteria1. Age minimal 18 years
2. Subjects with relapsed or refractory ITP (fulfilling the diagnostic criteria given in appendix A) and platelet numbers less than 30 x 10^9/l
3. Having completed first line treatment with corticosteroids
4. Written informed consent
5. World Health Organization (WHO) performance status less than or equal to 2
Key exclusion criteria1. The presence of an accessory spleen in splenectomized patients
2. Use of anticoagulants or chemotherapy or known other disorders and/or treatments influencing the platelet number within 3 months of randomisation date (tranexaminic acid [Cyklokapron®] treatment is allowed)
3. Pulsed or high dose corticosteroids, IVIG or splenectomy within 3 weeks prior to randomisation. Maintenance corticosteroid therapy is allowed.
4. Prior therapy with rituximab
5. ITP treatments (other than corticosteroids, IVIG or splenectomy) within 3 months prior to randomisation (e.g. cyclosporin, vincristine). Stable treatment with non-immunosuppressive medication (i.e. danazol, dapson, vitamin C) is permitted.
6. Inadequate renal and liver function, i.e. creatinine or bilirubin greater than 25 x the upper normal value
7. Neutrophil count less than 15 x 10^9/l and haemoglobin level less than 62 mmol/l
8. Active bleeding (defined by grade 3 or 4 according to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v3.0)
9. Pregnant or lactating
10. Systemic infections: active viral infections, including human immunodeficiency virus (HIV)
11. Seriously immunocompromised patients
12. Systemic autoimmune disorders (e.g. systemic lupus erythematosus [SLE])
13. Current malignant disease
14. Any experimental therapy within 30 days prior to randomisation
Date of first enrolment01/09/2005
Date of final enrolment01/05/2008

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Academic Medical Centre (AMC)
Amsterdam
1100 DE
Netherlands

Sponsor information

Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (The Netherlands) - Data Centre
Research organisation

Erasmus Medical Centre
Daniel den Hoed Kliniek
P.O. Box 5201
Rotterdam
3008 AE
Netherlands

Phone +31 (0)10 439 1568
Email hdc@erasmusmc.nl
Website http://www.hovon.nl
ROR logo "ROR" https://ror.org/056kpdx27

Funders

Funder type

Research organisation

Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (The Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan